Navigation Links
Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement
Date:6/30/2010

BALTIMORE, June 30 /PRNewswire/ -- Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed a patent infringement lawsuit against Invitrogen Corporation (Invitrogen) and CellzDirect, Inc. (CellzDirect) in the United States District Court for the Northern District of Illinois in Chicago and has moved for a preliminary injunction.  Invitrogen, the parent of CellzDirect, is itself a wholly-owned subsidiary of Life Technologies of Carlsbad, California.  The complaint alleges that certain processes and methods performed by CellzDirect associated with its in vitro drug testing services and its pooled cryopreserved hepatocyte products infringe one or more claims of U.S. Patent No. 7,604,929 (the '929 patent).  The complaint also alleges that Invitrogen is selling these infringing products and services, as well as inducing infringement of the '929 patent, and seeks monetary damages and injunctive relief.  

Last month, Celsis IVT successfully reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a similar patent infringement lawsuit involving the '929 patent.  Celsis is represented by Jordan Sigale and Adam Kelly of Loeb & Loeb LLP.

The '929 patent relates to processes and methods for producing cryopreserved hepatocytes.  In general, this technology combines hepatocytes from multiple donors to create large lots with targeted activity levels, the result of which is a product that speeds up decision making and reduces the time and cost of drug research.  Since 2005, Celsis IVT has used this novel technology to create its unique LiverPool™ products for drug discovery research.  Major pharmaceutical companies around the world have incorporated these LiverPool products into their standard research protocols.  Research conducted with LiverPool has confirmed its outstanding efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies.  Additional LiverPool product information is available online at www.celsis.com/liverpool.

"Celsis believes that innovations are the lifeblood of the life sciences industry.  Advancements must be protected and respected if we are to further the cause of cost-effective drug discovery," said Jay LeCoque, CEO of Celsis.  "We are extremely disappointed that we have been forced into this litigation, but the predatory pricing employed by Invitrogen and CellzDirect suggests a serious attempt to erode our patent-protected market position for the LiverPool product line."  He added, "These tactics are lowering, as well as undermining, the perceived value of new product innovations and inventions. We remain hopeful that the defendants will realize the serious impact of such a precedent on the entire life sciences industry, and that they will work with us to properly resolve this issue."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis Holdings, Inc., itself a subsidiary of Celsis International Ltd., is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development.  Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization.  Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research.  Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit www.celsis.com/ivt.

About Celsis International Ltd

Chicago-based Celsis International Ltd is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries.  Celsis divisions deliver substantial time and cost savings to customers while ensuring product quality and safety.  Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including the top 25 pharmaceutical companies worldwide. Details at www.celsis.com.


'/>"/>
SOURCE Celsis In Vitro, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis Receives Frost & Sullivan 2008 Best Practices Award
2. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
3. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
4. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
5. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
6. Chicago-Based Celsis International Goes Private
7. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
8. Celsis IVT Settles LiverPool Patent Infringement Suit With XenoTech, LLC
9. Celsis Rapid Detections Updated Drug Master Files (DMFs) Accepted by FDA
10. GBC Seeks Nominations for Regions Third Annual Bioscience Awards
11. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
Breaking Biology News(10 mins):